October 2025 in “Advanced Healthcare Materials” This study found that using a stevioside-based microneedle patch significantly increased minoxidil's solubility and skin absorption, promoting hair growth in animal models and achieving 67.5% area coverage by day 35, highlighting the potential of this novel delivery system for androgenetic alopecia treatment.
September 2025 in “Journal of Medicinal Chemistry” This study evaluated a chemically modified siRNA, AR-27 E-Chol, which effectively promoted hair regrowth and reduced androgen receptor gene expression in a DHT-induced mouse model of androgenetic alopecia, suggesting its potential as a novel therapeutic candidate.
August 2025 in “Scientific Reports” This study found that hair follicle transplantation improved wound healing in diabetic mice by promoting tissue regeneration and reducing inflammation, with follicles from normoglycemic conditions proving more effective than those from hyperglycemic environments.
August 2025 in “Biomaterials” In this study, researchers developed a novel therapy using the secretome of human fetal cartilage progenitor cells, which successfully regenerated functional hair follicles in animal models and significantly increased hair regrowth, suggesting potential as a new treatment for androgenic alopecia.
August 2025 in “Macromolecular Bioscience” This study found that microneedles co-delivering minoxidil and a nitric oxide donor effectively promoted hair growth and follicle transition to the growth phase in an alopecia mouse model, suggesting a promising new approach for androgenetic alopecia treatment.
July 2025 in “International Journal of Dermatology” 
June 2025 in “Stem Cell Research & Therapy” This review highlights recent advancements in androgenetic alopecia treatment, focusing on the dysregulated signaling pathways involved in hair follicle regeneration and exploring innovative therapeutic strategies, including small molecule modulators and gene editing technologies, which show promise in preclinical models.
May 2025 in “Frontiers in Bioengineering and Biotechnology” In this study, the researchers reported that a novel exosome-based treatment, EX104, effectively reversed hair follicle miniaturization and promoted hair growth in a mouse model of androgenetic alopecia, showing results comparable to minoxidil and surpassing it in stimulating capillary growth and follicular proliferation.
April 2025 in “ACS Applied Nano Materials” In AGA mouse models, this study found that the combination of nickel–copper nanozymes and minoxidil in dissolvable microneedles significantly enhanced hair regeneration and improved the hair follicle microenvironment by reducing reactive oxygen species and increasing vascular density, compared to minoxidil alone.
March 2025 in “Journal of Controlled Release” This study found that a biocomposite microneedle system, which includes selenium nanozyme and hypoxic extracellular vesicles, enhanced hair density and follicle diameter in androgenetic alopecia mice by fighting inflammation, promoting blood vessel growth, reducing reactive oxygen species, and counteracting androgen effects.
February 2025 in “Journal of Nanobiotechnology” This study developed a microneedle system using black phosphorus nanosheets and baicalin for treating androgenetic alopecia, finding it effectively enhanced drug penetration and follicular targeting while showing synergistic efficacy and safety in preclinical tests, including in vivo model efficacy against testosterone-induced hair loss.
January 2025 in “Journal of Controlled Release” This study developed a gas-propelled microneedle patch with puerarin/quercetin nanoparticles, which demonstrated improved hair-regenerating effects in an androgenetic alopecia mouse model by increasing drug delivery, alleviating oxidative stress, promoting angiogenesis, and rejuvenating senescent cells.
November 2024 in “ACS Materials Letters” This study developed a nitric oxide delivery system using PVA films and HA liposomes, which enhanced hair follicle vitality and repaired blood vessels in androgenic alopecia by promoting angiogenesis and reducing inflammation through the HIF-1 signaling pathway.
This case report explores a 28-year-old man with type 2 diabetes who experienced telogen effluvium, a type of hair loss, following treatment for euglycemic diabetic ketoacidosis with luseogliflozin, possibly triggered by physical stress related to his condition and treatment.
September 2024 in “Stem Cell Research & Therapy” This study found that extracellular vesicles derived from hyaluronic acid-stimulated induced pluripotent stem cells significantly improved hair growth in a model of androgenetic alopecia in mice by enhancing Wnt/β-catenin signaling and regulating androgen receptor activity, showing comparable results to the commonly used treatment finasteride.
May 2024 in “Chemical engineering journal” This study reports that a new minoxidil and epigallocatechin gallate co-loaded ionic liquids system showed superior efficacy in promoting hair regrowth in a mouse model of androgenic alopecia by activating hair follicle stem cells and improving microenvironment conditions, compared to existing minoxidil products.
2 citations
,
April 2024 in “Advanced Materials” This study tested a hydrogel microneedle patch delivering T reg attractants in mice with alopecia, finding it boosted regulatory T cell numbers at the site, leading to hair regrowth without causing peripheral immunosuppression, suggesting a potential new approach for autoimmune skin disease treatment.
April 2024 in “JAMA dermatology” In this randomized clinical trial, oral minoxidil was not superior to topical minoxidil in increasing hair density in men with androgenetic alopecia over 24 weeks, though photographic analysis suggested oral minoxidil may work better on the vertex area of the scalp.
This study found that an extract from Justicia procumbens may prevent hair loss in a mouse model of androgenic alopecia by enhancing hair follicle cell proliferation and improving hair characteristics.
October 2023 in “Bioactive Materials” This study developed a novel liposome-based delivery system for Minoxidil and nitric oxide, which showed promising results in promoting hair regrowth in an androgenetic alopecia model by enhancing transdermal absorption, prolonging skin retention, and reducing inflammation.
1 citations
,
December 2022 in “Bioactive Materials” In this study, researchers developed a nanocomposite microneedle patch containing copper/zinc dual-doped silica nanoparticles, which release substances to promote hair follicle regeneration by targeting various pathophysiological aspects of androgenic alopecia, presenting an effective anti-hair loss treatment strategy.
23 citations
,
January 2021 in “Biomedicine & Pharmacotherapy” This study found that dihydrotestosterone induced hair loss and changes in hair morphology in male C57BL/6 mice, effects that could be partially reversed by the AR antagonist bicalutamide.
27 citations
,
October 2020 in “Drugs” This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.
102 citations
,
July 2020 in “International journal of molecular sciences” This review discusses the effects of hormonal changes on hair follicles, concluding that hormones like androgens and estradiol significantly influence hair growth and cycle, while the roles of other hormones are still being researched.
65 citations
,
July 2020 in “Science Advances” Dermal exosomes with miR-218-5p boost hair growth by controlling β-catenin signaling.
5 citations
,
May 2020 in “Clinical and Experimental Dermatology” This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.
7 citations
,
January 2020 in “International Journal of Molecular Sciences” This study found that exposure to extremely low-frequency electromagnetic fields at specific intensities significantly enhanced human hair follicle cell activation and proliferation, suggesting a potential new treatment approach for alopecia.
33 citations
,
November 2019 in “Journal of Controlled Release” In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.
8 citations
,
August 2019 in “Journal of The American Academy of Dermatology” This study found that androgenetic alopecia is a significant yet under-recognized cause of hair loss in children and adolescents, often linked to family history and typically diagnosed by clinical examination.
49 citations
,
July 2019 in “British Journal of Dermatology” This study found that Wnt signalling agonists increase and antagonists decrease in human scalp follicles from telogen to early-anagen, with differences from the mouse model suggesting targeted interventions for hair growth disorders.
7 citations
,
June 2019 in “Australasian Journal of Dermatology” This review discusses the role of androgen hormones in the pathophysiology of childhood androgenetic alopecia and reports no clinical results.
40 citations
,
March 2018 in “Aesthetic Surgery Journal” This study found that a single injection of platelet-rich stroma significantly increased hair density in men with androgenetic alopecia within 6 to 12 weeks, with no reported side effects.
58 citations
,
December 2017 in “Journal of The European Academy of Dermatology and Venereology” This review highlights that microneedling shows some promise for improving hair growth in alopecia, particularly when used with other treatments, though more research is needed to establish its efficacy and protocols.
110 citations
,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
